Barclays
INMB icon

Barclays’s INmune Bio INMB Stock Holding History

Barclays’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.1K Sell
18,646
-13,372
-42% -$19.1K ﹤0.01% 4569
2025
Q4 		$49.9K Buy
32,018
+2,012
+7% +$3.59K ﹤0.01% 4743
2025
Q3 		$62.1K Sell
30,006
-7,980
-21% -$18.3K ﹤0.01% 4723
2025
Q2 		$87.7K Buy
37,986
+18,144
+91% +$133K ﹤0.01% 4616
2025
Q1 		$155K Sell
19,842
-12,177
-38% -$96.7K ﹤0.01% 4179
2024
Q4 		$150K Buy
32,019
+2,975
+10% +$15.5K ﹤0.01% 4433
2024
Q3 		$157K Buy
29,044
+24,906
+602% +$177K ﹤0.01% 4417
2024
Q2 		$36.5K Buy
+4,138
New +$40.8K ﹤0.01% 4315
2021
Q2 		– Sell
-1,667
Closed -$20K – 4962
2021
Q1 		$20K Sell
1,667
-1,146
-41% -$20.6K ﹤0.01% 4373
2020
Q4 		$48K Hold
2,813
– – ﹤0.01% 4423
2020
Q3 		$29K Buy
2,813
+2,812
+281,200% +$28.6K ﹤0.01% 4814
2020
Q2 		$0 Buy
+1
New +$5 ﹤0.01% 5874

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Barclays's INMB Position: Q1 2026 in Review

Barclays reduced its INmune Bio (INMB) stake by 42% in Q1 2026, selling an estimated $19.1K and leaving 18,646 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4569.

Barclays first reported a position in INMB in Q2 2020 and has held it in 12 quarters since. The position peaked at $157K in Q3 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Barclays held 18,646 shares of INmune Bio worth $21.1K as of Q1 2026.
  • Barclays sold 13,372 INmune Bio shares in Q1 2026, an estimated $19.1K.
  • INmune Bio made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4569 holding.
  • Barclays first reported a position in INmune Bio in Q2 2020 and has held it in 12 quarters since.
  • Barclays's INmune Bio position peaked at $157K in Q3 2024.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.